CE Marking for Medical Devices

Stripped to its essence, CE marking is a conformity assessment: you assemble evidence that your device meets the MDR’s general safety and performance requirements, and — for anything above Class I — an independent notified body checks that evidence before you may apply the mark. The evidence lives in the technical documentation, structured broadly along the lines of the MDR’s Annex II and III, and it has to hang together as one argument rather than a pile of disconnected reports.

That argument runs from device description and intended purpose, through design and manufacturing information, risk management, verification and validation, and into the clinical evidence and the post-market surveillance plan. The MDR is explicit that conformity is an ongoing state, not a one-time event, which is why the post-market side now carries real weight. We build the file as a coherent narrative so a reviewer can follow the thread from claim to evidence without hunting for it.

• Class I (non-sterile, non-measuring): largely self-declared.
• Class IIa, IIb, III: notified-body assessment required, rising in depth.
• Custom and implantable devices carry additional specific obligations.

The MDR classifies devices through a set of rules in its Annex VIII, turning on how invasive the device is, how long it is in contact with the body, whether it is active, and what it does. The jump from Class IIa to IIb to III is not just administrative — it changes the depth of the notified body’s assessment, the clinical evidence expected, and the timeline. A device pushed up a class by a rule you missed carries a far heavier burden than you budgeted for; one placed too low gets bounced.

Because the rules interact and edge cases are common, classification is where experienced judgement earns its keep. We work through the rules against your device’s actual intended purpose and construction, document the reasoning, and set the conformity route before any file is built — so the whole project is scoped correctly from day one rather than re-scoped painfully halfway through.

If the MDR has a reputation, it is for clinical evidence. The regulation expects a robust Clinical Evaluation Report that demonstrates the device’s safety and performance, and it has narrowed the room to lean purely on equivalence to another manufacturer’s device. For many products that once rode on a thin clinical rationale, the honest answer under the MDR is that more data — sometimes a clinical investigation — is needed, and discovering that late is one of the most expensive surprises in the whole process.

We assess your clinical situation early and truthfully: what evidence you have, whether equivalence is genuinely defensible, and what gap remains. Then we plan the clinical evaluation — literature, existing data, post-market clinical follow-up, and where necessary investigations — so the CER stands up to a notified body rather than inviting a round of deficiency questions that stall the whole file.

For everything above Class I, the notified body does not only review your file — it audits your quality management system, and for medical devices that system is built on ISO 13485. The technical file and the QMS are two halves of the same story: the file shows the device is safe and effective; the QMS shows you can make it that way, consistently, and catch problems when they arise. A strong file behind a weak quality system does not pass.

Because the same ISO 13485 system underpins CE marking, CDSCO manufacturing and other markets, we build or align it once with all of those endpoints in mind. That saves you from maintaining parallel systems for different regulators and means the audit that supports your CE certificate also supports the rest of your regulatory roadmap.

Under the MDR, notified-body capacity is genuinely tight, and not every notified body is designated for every device type. Choosing one that is designated for your device, has reasonable timelines, and is a sensible fit for your size is a real decision that affects how long the whole thing takes. The wrong choice can leave you waiting months just to get into a queue, before the substantive review even begins.

We help you select an appropriate notified body, prepare the submission the way that body likes to receive it, and manage the review — answering deficiency questions quickly and completely so momentum is not lost. In a system where a slow query response can cost you your slot, disciplined query handling is not a nicety; it is what keeps your certificate on schedule.

• Notified body must be designated for your specific device type.
• Capacity is limited — queue times are a real planning factor.
• Fast, complete deficiency responses protect your timeline.

A manufacturer based outside the European Union cannot place a device on the EU market alone. The MDR requires you to appoint an EU Authorised Representative (often shortened to EC REP) established in the Union, who takes on defined legal responsibilities, appears on your labelling, and is a point of contact for the authorities. It is a genuine legal role, not a mailbox, and the responsibilities are set out in the regulation.

We guide non-EU manufacturers through appointing a suitable authorised representative, getting the mandate and responsibilities right, and reflecting the EC REP correctly on labelling and documentation. Combined with the import and registration requirements of individual member states, this is the practical machinery that turns a CE certificate into actual sales on the ground.

Few manufacturers pursue Europe in isolation. The clinical evidence, risk management and quality system you build for the MDR are largely the same assets you need for a US 510(k), a CDSCO registration, or other markets — if they are built with that reuse in mind. Treated as separate projects, each market becomes a fresh mountain; treated as one evidence base with market-specific wrappers, the second and third approvals come far more cheaply.

We plan CE marking as part of your overall market-access strategy, so the CER, the risk file and the QMS you invest in for Europe also carry weight in the other submissions you are heading towards. If your roadmap includes the US, we align the work with FDA 510(k) submission; if it includes India, with your CDSCO registration. One coherent evidence base, several markets.